Xeris Biopharma Holdings, Inc. (0A8E)
London Exchange · UK · prices in USD · close of 19 Oct 2026
Key indicators
| Last close | USD 11.29 |
|---|---|
| 52-week range | 5.26 – 11.38 |
| Return, 1 month / 3 months | +37.7% / +28.5% |
| Return, 1 year / 3 years | – / – |
| Trend | Uptrend |
| RSI (14) | 73 |
| Volatility (1 year) | 51.9% |
| Worst drawdown (1 year) | -35.4% |
| Average daily value traded | 0.03M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Xeris Biopharma Holdings is a pharmaceutical company based in Chicago that develops and commercialises injectable medicines. It uses its own formulation technologies to make drugs that can be given by injection, including ready-to-use liquid forms of treatments that were previously supplied as powders needing mixing. Its products serve patients with endocrine and neuromuscular conditions, and it also works with other drug developers who use its formulation platforms for their own medicines.
Xeris Biopharma Holdings, Inc. trades under the code 0A8E on the London Exchange in UK, with its price quoted in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Xeris Biopharma Holdings, Inc. (0A8E) trades on the London Exchange in UK. It last closed at USD 11.29 on 19 October 2026.
Its price-based Market X-Ray is 65 out of 100 (a fair price profile), ranking 897 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 96 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 53.3% | ||
| From 52-week high | 0.0% | ||
| Momentum | 95 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 28.5% | ||
| 6-month return | 92.9% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 32 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 51.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -35.4% | ||
| Liquidity | 20 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.03M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +9.1% |
|---|---|
| 1 month | +37.7% |
| 3 months | +28.5% |
| 6 months | +92.9% |
| 1 year | – |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 8.92 / 7.36 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.45 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.